Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Score Huge with Open Record Rewards - 2Pick Your Favored kind of sandwich
- 3Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- 4Vote In favor of Your Number one Sort Of Blossoms
- 5JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- 4 astronauts are now on their path to the moon. Here’s what happens next
- Ancient mass grave discovered in water cistern during Tel Azekah excavations
- Fundamental Home Items Each Animal person Needs
- The Meaning of Breaking the Pen's Nib in Death penalties
- 5 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- NASA is shooting for the moon. A guide to the Artemis II mission
- Kendall Jenner addresses long-standing rumor about her sexuality
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
